Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - Антитромботични агенти - possia, прилага с Ацетилсалицилова киселина (АСК) е показан за предпазване от атеротромботични инциденти при възрастни пациенти с остри коронарни синдроми (нестабилна стенокардия, non-st-елевация миокарден инфаркт [nstemi] или st-елевация инфаркт на миокарда [stemi]); включително пациенти, управлявани медицински и тези, които се управляват с перкутанна коронарна интервенция (pci) или коронарна артерия байпас (cabg) присаждане.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, бримонидин тартрат - ocular hypertension; glaucoma, open-angle - Офталмологични - Намаляване на повишено вътреочно налягане (ВО) при възрастни пациенти с глаукома с отворен ъгъл или очна хипертония, при които монотерапията не осигурява достатъчно намаляване на ВОН.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

pharma mar s.a. - трабектедин - ovarian neoplasms; sarcoma - Антинеопластични средства - yondelis е показан за лечение на пациенти с напреднал сарком на меките тъкани, след провала на антрациклини и ифосфамид, или които са неподходящи за получаване на тези агенти. Данните за ефикасността се основават основно на пациенти с липосаркома и лейомиосаркома. Йонделис в комбинация с пегилированным липосомальным доксорубицином (pld) е показан за лечение на пациенти с рецидивиращи platino-чувствителни рак на яйчниците .

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

co.don gmbh - сфероиди на хондроцити, свързани с човешка автоложна матрица - Хронични заболявания - Други лекарства за нарушения на мускулно-скелетната система - Ремонт на дефекти на симптоматична ставния хрущял на бедрената кондила и патела на коляното (Международната хрущял ремонт общество [icrs] клас iii или iv) с дефект размери до 10 cm2 при възрастни.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - Анемия, сърповидна клетка - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - Множествена Склероза, Рецидивно-Ремиттирующее - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - Болест и чернодробна терапия - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 и 5.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.